• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks

    Merck Receives FDA Approval for ZINPLAVA™

    Chelsea Pratt
    Oct. 21, 2016 06:57PM PST
    Pharmaceutical Investing

    Merck today announced that the U.S. Food and Drug Administration (FDA) has approved ZINPLAVA™ (bezlotoxumab) Injection 25 mg/mL.

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved ZINPLAVA™ (bezlotoxumab) Injection 25 mg/mL. Merck anticipates
    making ZINPLAVA available in first quarter 2017.
    ZINPLAVA is indicated to reduce recurrence of Clostridium difficile infection
    (CDI) in patients 18 years of age or older who are receiving
    antibacterial drug treatment of CDI and are at high risk for CDI
    recurrence. ZINPLAVA is not indicated for the treatment of CDI. ZINPLAVA
    is not an antibacterial drug. ZINPLAVA should only be used in
    conjunction with antibacterial drug treatment of CDI.
    CDI is caused by bacteria that produce toxins, including toxin B.
    Symptoms of CDI include mild-to-severe diarrhea, abdominal pain and
    fever. The incidence of recurrent CDI is higher in certain patient
    populations, including people 65 years of age or older and those with
    compromised immune systems.
    “For generations, Merck has been steadfast in its commitment to fighting
    infectious diseases – and that commitment continues today. ZINPLAVA is a
    human monoclonal antibody that binds to C. difficile toxin B and
    neutralizes its effects,” said Dr. Nicholas Kartsonis, vice president of
    clinical development, infectious diseases, Merck Research Laboratories.
    Selected safety information about ZINPLAVA
    Heart failure was reported more commonly in the two Phase 3 clinical
    trials in ZINPLAVA-treated patients compared to placebo-treated
    patients. These adverse reactions occurred primarily in patients with
    underlying congestive heart failure (CHF). In patients with a history of
    CHF, 12.7% (15/118) of ZINPLAVA-treated patients and 4.8% (5/104) of
    placebo-treated patients had the serious adverse reaction of heart
    failure during the 12-week study period. Additionally, in patients with
    a history of CHF, there were more deaths in ZINPLAVA-treated patients
    [19.5% (23/118)] than in placebo-treated patients [12.5% (13/104)]
    during the 12-week study period. The causes of death varied, and
    included cardiac failure, infections, and respiratory failure. In
    patients with a history of CHF, ZINPLAVA (bezlotoxumab) should be
    reserved for use when the benefit outweighs the risk.
    The most common adverse reactions occurring within 4 weeks of infusion
    with a frequency greater than placebo and reported in ≥4% of patients
    treated with ZINPLAVA and Standard of Care (SoC) antibacterial drug
    therapy vs placebo and SoC antibacterial drug therapy included nausea
    (7% vs 5%), pyrexia (5% vs 3%) and headache (4% vs 3%).
    Serious adverse reactions occurring within 12 weeks following infusion
    were reported in 29% of ZINPLAVA-treated patients and 33% of
    placebo-treated patients. Heart failure was reported as a serious
    adverse reaction in 2.3% of ZINPLAVA-treated patients and 1.0% of
    placebo-treated patients.
    In ZINPLAVA-treated patients, 10% experienced one or more infusion
    specific adverse reactions compared to 8% of placebo-treated patients,
    on the day of or the day after, the infusion. Infusion specific adverse
    reactions reported in ≥0.5% of patients receiving ZINPLAVA and at a
    frequency greater than placebo were nausea (3%), fatigue (1%), pyrexia
    (1%), dizziness (1%), headache (2%), dyspnea (1%) and hypertension (1%).
    Of these patients, 78% experienced mild adverse reactions, and 20% of
    patients experienced moderate adverse reactions. These reactions
    resolved within 24 hours following onset.
    As with all therapeutic proteins, there is a potential for
    immunogenicity following administration of ZINPLAVA. The detection of
    antibody formation is highly dependent on the sensitivity and
    specificity of the assay. Additionally, the observed incidence of
    antibody (including neutralizing antibody) positivity in an assay may be
    influenced by several factors including assay methodology, sample
    handling, timing of sample collection, concomitant medications, and
    underlying disease. For these reasons, comparison of the incidence of
    antibodies to bezlotoxumab in two Phase 3 studies with the incidence of
    antibodies in other studies or to other products may be misleading.
    Following treatment with ZINPLAVA in these two studies, none of the 710
    evaluable patients tested positive for treatment-emergent
    anti-bezlotoxumab antibodies.
    About bezlotoxumab
    Bezlotoxumab was developed by researchers at the University of
    Massachusetts Medical School’s MassBiologics Laboratory in conjunction
    with Medarex (now part of Bristol-Myers Squibb), and was licensed to
    Merck in 2009.
    About Merck
    For 125 years, Merck has been a global health care leader working to
    help the world be well. Merck is known as MSD outside the United States
    and Canada. Through our prescription medicines, vaccines, biologic
    therapies, and animal health products, we work with customers and
    operate in more than 140 countries to deliver innovative health
    solutions. We also demonstrate our commitment to increasing access to
    health care through far-reaching policies, programs and partnerships.
    For more information, visit www.merck.com
    and connect with us on Twitter,
    Facebook,
    YouTube
    and LinkedIn.
    Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
    This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the
    “company”) includes “forward-looking statements” within the meaning of
    the safe harbor provisions of the U.S. Private Securities Litigation
    Reform Act of 1995. These statements are based upon the current beliefs
    and expectations of the company’s management and are subject to
    significant risks and uncertainties. There can be no guarantees with
    respect to pipeline products that the products will receive the
    necessary regulatory approvals or that they will prove to be
    commercially successful. If underlying assumptions prove inaccurate or
    risks or uncertainties materialize, actual results may differ materially
    from those set forth in the forward-looking statements.
    Risks and uncertainties include but are not limited to, general industry
    conditions and competition; general economic factors, including interest
    rate and currency exchange rate fluctuations; the impact of
    pharmaceutical industry regulation and health care legislation in the
    United States and internationally; global trends toward health care cost
    containment; technological advances, new products and patents attained
    by competitors; challenges inherent in new product development,
    including obtaining regulatory approval; the company’s ability to
    accurately predict future market conditions; manufacturing difficulties
    or delays; financial instability of international economies and
    sovereign risk; dependence on the effectiveness of the company’s patents
    and other protections for innovative products; and the exposure to
    litigation, including patent litigation, and/or regulatory actions.
    The company undertakes no obligation to publicly update any
    forward-looking statement, whether as a result of new information,
    future events or otherwise. Additional factors that could cause results
    to differ materially from those described in the forward-looking
    statements can be found in the company’s 2015 Annual Report on Form 10-K
    and the company’s other filings with the Securities and Exchange
    Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
    Please see Prescribing Information for ZINPLAVA (bezlotoxumab) at https://www.merck.com/product/usa/pi_circulars/z/zinplava/zinplava_pi.pdf
    and

    Patient Information for ZINPLAVA at https://www.merck.com/product/usa/pi_circulars/z/zinplava/zinplava_ppi.pdf

    clinical trialsfood and drug administrationdrug therapycanada
    The Conversation (0)

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×